GKOS Quote, Financials, Valuation and Earnings

Boston Scientific has a net margin of -22.15% compared to Glaukos's net margin of 11.12%. Glaukos's return on equity of -27.46% beat Boston Scientific's return on equity of 8.91%.

Glaukos has a consensus price target of --, signalling downside risk potential of -1.51%. On the other hand Boston Scientific has an analysts' consensus of $99.26 which suggests that it could grow by 10.69%. Given that Boston Scientific has higher upside potential than Glaukos, analysts believe Boston Scientific is more attractive than Glaukos.

Glaukos has a beta of 1.034, which suggesting that the stock is 3.395% more volatile than S&P 500. In comparison Boston Scientific has a beta of 0.802, suggesting its less volatile than the S&P 500 by 19.799%.

Glaukos has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Glaukos pays -- of its earnings as a dividend. Boston Scientific pays out 1.76% of its earnings as a dividend. Boston Scientific's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Glaukos quarterly revenues are $96.7M, which are smaller than Boston Scientific quarterly revenues of $4.2B. Glaukos's net income of -$21.4M is lower than Boston Scientific's net income of $468M. Notably, Glaukos's price-to-earnings ratio is -- while Boston Scientific's PE ratio is 74.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Glaukos is 21.18x versus 8.36x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Globus Medical has a net margin of -22.15% compared to Glaukos's net margin of 8.28%. Glaukos's return on equity of -27.46% beat Globus Medical's return on equity of 2.27%.

Glaukos has a consensus price target of --, signalling downside risk potential of -1.51%. On the other hand Globus Medical has an analysts' consensus of $94.23 which suggests that it could grow by 13.98%. Given that Globus Medical has higher upside potential than Glaukos, analysts believe Globus Medical is more attractive than Glaukos.

Glaukos has a beta of 1.034, which suggesting that the stock is 3.395% more volatile than S&P 500. In comparison Globus Medical has a beta of 1.190, suggesting its more volatile than the S&P 500 by 19.035%.

Glaukos has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Globus Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Glaukos pays -- of its earnings as a dividend. Globus Medical pays out -- of its earnings as a dividend.

Glaukos quarterly revenues are $96.7M, which are smaller than Globus Medical quarterly revenues of $625.7M. Glaukos's net income of -$21.4M is lower than Globus Medical's net income of $51.8M. Notably, Glaukos's price-to-earnings ratio is -- while Globus Medical's PE ratio is 123.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Glaukos is 21.18x versus 4.57x for Globus Medical. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical has a net margin of -22.15% compared to Glaukos's net margin of 27.73%. Glaukos's return on equity of -27.46% beat Intuitive Surgical's return on equity of 15.9%.

Glaukos has a consensus price target of --, signalling downside risk potential of -1.51%. On the other hand Intuitive Surgical has an analysts' consensus of $556.42 which suggests that it could grow by 5.59%. Given that Intuitive Surgical has higher upside potential than Glaukos, analysts believe Intuitive Surgical is more attractive than Glaukos.

Glaukos has a beta of 1.034, which suggesting that the stock is 3.395% more volatile than S&P 500. In comparison Intuitive Surgical has a beta of 1.383, suggesting its more volatile than the S&P 500 by 38.272%.

Glaukos has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Glaukos pays -- of its earnings as a dividend. Intuitive Surgical pays out -- of its earnings as a dividend.

Glaukos quarterly revenues are $96.7M, which are smaller than Intuitive Surgical quarterly revenues of $2B. Glaukos's net income of -$21.4M is lower than Intuitive Surgical's net income of $565.1M. Notably, Glaukos's price-to-earnings ratio is -- while Intuitive Surgical's PE ratio is 84.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Glaukos is 21.18x versus 24.16x for Intuitive Surgical. Usually stocks with elevated PS ratios are considered overvalued.

Masimo has a net margin of -22.15% compared to Glaukos's net margin of 1.94%. Glaukos's return on equity of -27.46% beat Masimo's return on equity of 5.75%.

Glaukos has a consensus price target of --, signalling downside risk potential of -1.51%. On the other hand Masimo has an analysts' consensus of $175.77 which suggests that it could grow by 4.26%. Given that Masimo has higher upside potential than Glaukos, analysts believe Masimo is more attractive than Glaukos.

Glaukos has a beta of 1.034, which suggesting that the stock is 3.395% more volatile than S&P 500. In comparison Masimo has a beta of 1.010, suggesting its more volatile than the S&P 500 by 1.04%.

Glaukos has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Masimo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Glaukos pays -- of its earnings as a dividend. Masimo pays out -- of its earnings as a dividend.

Glaukos quarterly revenues are $96.7M, which are smaller than Masimo quarterly revenues of $504.6M. Glaukos's net income of -$21.4M is lower than Masimo's net income of $9.8M. Notably, Glaukos's price-to-earnings ratio is -- while Masimo's PE ratio is 116.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Glaukos is 21.18x versus 4.49x for Masimo. Usually stocks with elevated PS ratios are considered overvalued.